Dash Bio
Boston, Massachusetts, United States · Biotechnology · 9 employees
Dash Bio is revolutionizing clinical bioanalysis to expedite drug development. By leveraging AI and robotics, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average for clinical trials and GLP studies.
Funding history
- Funding Round — $11.0M — Jun 2025
- Series seed — $6.5M — Oct 2024
Recent signals
- Jun 26, 2025: Raised $11.0M
- Oct 28, 2024: Raised $6.5M in Series seed
See plans & pricing → Track Dash Bio’s funding, hiring, and signals — with verified contacts — on Fundz.